XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer

Chinese Medical Journal

Volumn 123, Issue 23, 2010, Pages 3427-3432

  Zhu, Xiao Li ^a   Sun, Xin Chen ^a   Chen, Bao An ^a   Sun, Ning ^b   Cheng, Hong Yan ^a   Li, Fan ^a   Zhang, Hong Ming ^a   Feng, Ji Feng ^b   Qin, Shu Kui ^c   Cheng, Lu ^d   Lu, Zu Hong ^d  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c 81th Hospital of People's Liberation Army   (China)

^d SOUTHEAST UNIVERSITY   (China)

Author keywords

Chemotherapy; Gene chip microarray; Non small cell lung cancer; Single nucleotide polymorphism; Xeroderma pigmentosum group C

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MULTICENTER STUDY; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; XPC GENE;

ADULT; AGED; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA-BINDING PROTEINS; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES;

EID: 78649885310     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.23.010     Document Type: Article

References (32)

1. Yang L, Parkin DM, Li LD, Chen YD, Bray F. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 2004; 90: 2157-2166.
2. Reed E. Platinum-DNA adduct nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24: 331-344.
3. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1513-1530.
4. Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity In non-small cell lung cancer patients. Clin Cancer Res 2005; 11: 1534-1538.
5. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005; 4: 18.
6. Fedier A, Fink D. Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity. Int J Oncol 2004; 24: 1039-1047.
7. Allan JM, Smith AG, Wheatley K, Hills RK, Travis LB, Hill DA, et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004; 104: 3872-3877.
8. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced nonsmall cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939-4943.
9. Auranen A, Song H, Waterfall C, Dicioccio RA, Kuschel B, Kjaer SK, et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 2005; 117: 611-618.
10. Price N. Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer. Clin Lung Cancer 2004; 6: 79-82.
11. Chang-Claude J, Popanda O, Tan XL, Kropp S, Helmbold I, von Fournier D, et al. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 2005; 11: 4802-4809.
12. Sugasawa K, Ng JM, Masutani C, Iwai S, van der Spek PJ, Eker AP, et al. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol Cell 1998; 2: 223-232.
13. Zhou RM, Li Y, Wang N, Zhang XJ, Dong XJ, Guo W. Correlation of XPC Ala499Val and Lys939GIn polymorphisms to risks of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Cancer (Chin) 2006; 25: 1113-1119.
14. An J, Liu Z, Hu Z, Li G, Wang LE, Sturgis EM, et al. Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 2007; 16: 1633-1638.
15. Kristensen VN, Edvardsen H, Tsalenko A, Nordgard SH, Sørlie T, Sharan R, et al. Genetic variation in putative regulatory loci controlling gene expression in breast cancer. Proc Natl Acad Sci U S A 2006; 103: 7735-7740.
16. Hirata H, Hinoda Y, Matsuyama H, Tanaka Y, Okayama N, Suehiro Y, et al. Polymorphisms of DNA repair genes are associated with renal cell carcinoma. Biochem Biophys Res Commun 2006; 342: 1058-1062.
17. Figueroa JD, Malats N, Real FX, Silverman D, Kogevinas M, Chanock S, et al. Genetic variation in the base excision repair pathway and bladder cancer risk. Hum Genet 2007; 121: 233-242.
18. Huang WY, Berndt SI, Kang D, Chatterjee N, Chanock SJ, Yeager M, et al. Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: XPC polymorphisms modify smoking-related risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 306-311.
19. Kietthubthew S, Sriplung H, Au WW, Ishida T. Polymorphism in DNA repair genes and oral squamous cell carcinoma in Thailand. Int J Hyg Environ Health 2006; 209: 21-29.
20. Vogel U, Overvad K, Wallin H, Tjønneland A, Nexø BA, Raaschou-Nielsen O. Combinations of polymorphisms in XPD, XPC and XPA in relation to risk of lung cancer. Cancer Lett 2005; 222: 67-74.
21. McWilliams RR, Bamlet WR, Cunningham JM, Goode EL, de Andrade M, Boardman LA, et al. Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res 2008; 68: 4928-4935.
22. Qiu L, Wang ZX, Shi XQ, Wang ZZ. Associations between XPC polymorphisms and risk of cancers: a meta-analysis. Eur J Cancer 2008; 44: 2241-2253.
23. Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Zhang XR, et al. Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy. Cancer (Chin) 2005; 24: 1510-1513.
24. Khan SG, Metter EJ, Tarone RE, Bohr VA, Grossman L, Hedayati M, et al. A new xeroderma pigmentosum group C poly(AT) insertion/deletion polymorphism. Carcinogenesis 2000; 21: 1821-1825.
25. Francisco G, Menezes PR, Eluf-Neto J, Chammas R. XPC polymorphisms play a role in tissue-specific carcinogenesis: a meta-analysis. Eur J Hum Genet 2008; 16: 724-734.
26. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
27. Xiao PF, Cheng L, Wan Y, Sun BL, Chen ZZ, Zhang SY, et al. An improved gel-based DNA microarray method for detecting single nucleotide mismatch. Electrophoresis 2006; 27: 3904-3915.
28. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
29. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
30. Vicent G, Mar T. Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk Lymphoma 2008; 49: 204-217.
31. Gao R, Price DK, Sissung T, Reed E, Figg WD. Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Mol Cancer Ther 2008; 7: 1246-1250.
32. Xiao PF, Huang H, Zhou GH, Lu Z. Gel immobilization of acrylamide-modified single-stranded DNA template for pyrosequencing. Electrophoresis 2007; 28: 1903-1912.